Codexis Enters into Research Collaboration with Schering-Plough
News Mar 22, 2006
The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.
Codexis will receive research funding and milestone payments upon completion of certain objectives of the research.
"We are pleased to add Schering-Plough to our list of industry-leading pharmaceutical partners," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
"We are delighted to see a growing number of major pharmaceutical companies recognizing the competitive advantage and cost-savings value that Codexis' technology brings to the manufacturing process for clinical-scale production and product commercialization, and look forward to continued adoption of our technology across the pharmaceutical industry."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE